Exhibition Information at a Glance:
Dates: June 16-18, 2026
Location: Shanghai New International Expo Centre
Booth Number: E7G36
At a critical juncture of accelerated transformation in the global pharmaceutical industry, Shanghai Lizhuo, a professional company specializing in the R&D and production of pharmaceutical intermediates, will participate in CPHI China 2026 to showcase its latest breakthroughs in high-quality APIs, pharmaceutical intermediates, and customized synthesis services. Leveraging the CPHI global series of exhibitions, Shanghai Lizhuo not only focuses on the Chinese market but also strives to connect with global pharmaceutical innovation resources.
From June 16-18, 2026, at the Shanghai New International Expo Centre, Shanghai Lizhuo looks forward to meeting you at CPHI China 2026. Let us explore new paths for innovative development in the global pharmaceutical industry on this important platform that drives its transformation and upgrading, and jointly contribute Chinese wisdom and strength to global health.
Shanghai Lizhuo invites you to Shanghai to create a new future for the pharmaceutical industry!
With the number of people suffering from diabetes and obesity rising globally, a revolutionary oral medication is changing the landscape of treatment. Ogliflozin, a novel small-molecule, non-peptide oral GLP-1 receptor agonist discovered by Chugai Pharmaceutical Co., Ltd. of Japan and licensed to Eli Lilly and Company in 2018, is bringing new hope to hundreds of millions of patients. Lizhuo Pharmaceutical recently achieved industrial-scale production of two important pharmaceutical intermediates: 5-bromo-1-cyclopropyl-4-fluoro-1H-indazole (CAS NO. 2490501-34-1) and 5-bromo-4-fluoro-1H-indazole (CAS NO. 1082041-85-7). Since its launch, this series of high-purity intermediates has gained the continued trust of domestic and international markets due to its excellent product quality and reliable supply capabilities.
Post time: Feb-03-2026
